|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | 0.00% |
|
+11.11% | -44.44% |
| 02/05 | OncoSil Medical Raises AU$5.3 Million under Entitlement Offer | MT |
| 18/04 | OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial | MT |
OncoSil Medical Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was AUD 0.367677 million compared to AUD 0.231789 million a year ago. Net loss was AUD 11.34 million compared to AUD 10.73 million a year ago.
Basic loss per share from continuing operations was AUD 0.01 compared to AUD 0.0132 a year ago. Diluted loss per share from continuing operations was AUD 0.01 compared to AUD 0.0132 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -44.44% | 89.59L | |
| +31.37% | 59TCr | |
| -2.60% | 36TCr | |
| +20.83% | 33TCr | |
| +5.69% | 29TCr | |
| +14.83% | 24TCr | |
| +9.93% | 21TCr | |
| -6.95% | 20TCr | |
| +10.77% | 17TCr | |
| +0.10% | 16TCr |
ONCOSIL MEDICAL LIMITED 